Toll Free: 1-888-928-9744

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016', provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) 
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Overview 9 Therapeutics Development 10 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Stage of Development 10 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Therapy Area 11 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Indication 12 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Companies 17 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Universities/Institutes 20 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development 29 BioApex, s.r.o. 29 C4X Discovery Holdings PLC 30 Catabasis Pharmaceuticals, Inc. 31 Evgen Pharma Plc 32 Ixchel Pharma, LLC 33 Jiangsu Hengrui Medicine Co., Ltd. 34 Reata Pharmaceuticals, Inc. 35 Rigel Pharmaceuticals, Inc. 36 XenoPort, Inc. 37 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles 38 BA-1521 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 bardoxolone methyl - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 CAT-4001 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 dimethyl fumarate DR - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 IXC-101 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 IXC-103 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 LH-503 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 LH-526 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 MG-132 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 MIND-4 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 monosodium luminol - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 omaveloxolone - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 R-970 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 SFX-02 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 SFX-03 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecule to Activate Nrf2 for Inflammation - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecules to Activate NRF-2 for COPD and Multiple Sclerosis - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules to Activate Nrf2 for Cancer and Inflammation - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules to Activate Nrf2 for Inflammation - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Sulforadex - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 TBE-31 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 trigonelline hydrochloride - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 VEDA-1209 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 XP-23829 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Projects 78 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products 83 Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Featured News & Press Releases 84 Jul 05, 2016: Bach Pharma Appoints Kelly Blackburn as Chief Executive Officer 84 Jun 23, 2016: Reata Pharmaceuticals Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension 84 May 03, 2016: Evgen Pharma: First Patient Dosed in Phase II Clinical Trial in SAH 85 Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness 85 Apr 12, 2016: Biogen to Present Data on TECFIDERA at 2016 AAN Annual Meeting 88 Mar 02, 2016: Approval of Phase II Clinical Trial in SAH 89 Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia 90 Jan 05, 2016: Reata Enrolls First Patient with Pulmonary Hypertension Associated with Interstitial Lung Disease in LARIAT, a Phase 2 Study Examining Bardoxolone Methyl for the Treatment of Patients with Pulmonary Hypertension 90 Oct 27, 2015: Reata Announces Initial Phase 2 Pulmonary Arterial Hypertension Data for Bardoxolone Methyl and Planned Initiation of Phase 3 Study 91 Oct 23, 2015: Updated recommendations to minimize the risk of the rare brain infection PML with Tecfidera 93 Oct 07, 2015: New Data Show Strong, Sustained Effects of TECFIDERA in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients 95 Oct 01, 2015: Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, On New TECFIDERA Data Demonstrating Importance of Early Treatment 98 Sep 16, 2015: Reata to Present Initial Phase 2 Data on Bardoxolone Methyl, a Novel Experimental Therapy for Pulmonary Hypertension Used in Patients on Stable Background PAH Therapy 99 Sep 15, 2015: XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis 99 Sep 02, 2015: USPTO Dismisses Inter Partes Review Petition of Biogen's Patent 514 for TECFIDERA (Dimethyl Fumarate) 101 Appendix 102 Methodology 102 Coverage 102 Secondary Research 102 Primary Research 102 Expert Panel Validation 102 Contact Us 102 Disclaimer 103
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Comparative Analysis by Unknown Stage Development, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Pipeline by BioApex, s.r.o., H2 2016 29 Pipeline by C4X Discovery Holdings PLC, H2 2016 30 Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 31 Pipeline by Evgen Pharma Plc, H2 2016 32 Pipeline by Ixchel Pharma, LLC, H2 2016 33 Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 34 Pipeline by Reata Pharmaceuticals, Inc., H2 2016 35 Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 36 Pipeline by XenoPort, Inc., H2 2016 37 Dormant Projects, H2 2016 78 Dormant Projects (Contd..1), H2 2016 79 Dormant Projects (Contd..2), H2 2016 80 Dormant Projects (Contd..3), H2 2016 81 Dormant Projects (Contd..4), H2 2016 82 Discontinued Products, H2 2016 83



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify